Q3 2024 Holdings
Filed 2024-11-14 | 45 holdings | $1.9B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $428.3M | 8,494,151 | 22.7% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $114.3M | 1,000,000 | 6.1% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $104.4M | 1,250,000 | 5.5% |
| Longboard Pharmaceuticals in | COM | 54300N103 | $93.0M | 2,790,462 | 4.9% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $90.9M | 3,406,534 | 4.8% |
| Eyepoint Pharmaceuticals Inc(EYPT) | COM NEW | 30233G209 | $66.5M | 8,325,000 | 3.5% |
| Rapport Therapeutics Inc(RAPP) | COM | 75383L102 | $60.2M | 2,940,921 | 3.2% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $56.2M | 1,100,000 | 3.0% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $50.1M | 870,000 | 2.7% |
| Corbus Pharmaceuticals Hldgs(CRBP) | COM NEW | 21833P301 | $49.0M | 2,375,000 | 2.6% |
| Avidity Biosciences Inc(RNA) | COM | 05370A108 | $48.2M | 1,050,000 | 2.6% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $47.7M | 1,050,000 | 2.5% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $47.3M | 1,858,351 | 2.5% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $41.0M | 2,470,000 | 2.2% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $41.0M | 2,561,600 | 2.2% |
| Merus N V | COM | N5749R100 | $37.0M | 740,000 | 2.0% |
| CG Oncology Inc(CGON) | COM | 156944100 | $36.8M | 975,000 | 2.0% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $36.5M | 500,000 | 1.9% |
| Biomea Fusion Inc(BMEA) | COM | 09077A106 | $36.1M | 3,570,872 | 1.9% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $35.9M | 400,000 | 1.9% |
| Bioage Labs Inc(BIOA) | COM | 09077V100 | $33.9M | 1,629,529 | 1.8% |
| Helix Acquisition Corp II | CL A ORD SHS | G4444H101 | $30.4M | 2,909,000 | 1.6% |
| Pharvaris N V(PHVS) | COM | N69605108 | $27.2M | 1,466,460 | 1.4% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $24.5M | 2,130,000 | 1.3% |
| Alumis Inc(ALMS) | COM | 022307102 | $22.9M | 2,147,396 | 1.2% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $21.8M | 1,182,563 | 1.2% |
| Arcutis Biotherapeutics Inc(ARQT) | COM | 03969K108 | $21.6M | 2,325,000 | 1.1% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $21.0M | 400,000 | 1.1% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $20.1M | 401,963 | 1.1% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $19.7M | 1,550,000 | 1.0% |
| Y-Mabs Therapeutics Inc(YMABUSD) | COM | 984241109 | $19.1M | 1,450,000 | 1.0% |
| MBX Biosciences Inc(MBX) | COM | 55287L101 | $18.2M | 700,000 | 1.0% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $16.4M | 500,000 | 0.9% |
| Arrivent Biopharma Inc(AVBP) | COM | 04272N102 | $13.8M | 585,462 | 0.7% |
| Anaptysbio Inc(ANAB) | COM | 032724106 | $11.5M | 342,465 | 0.6% |
| Korro BIO Inc(KRRO) | COM | 500946108 | $8.9M | 265,826 | 0.5% |
| Silence Therapeutics PLC(SLN) | ADS | 82686Q101 | $7.3M | 400,000 | 0.4% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $6.6M | 1,000,000 | 0.3% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $5.2M | 427,163 | 0.3% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $4.5M | 107,344 | 0.2% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $4.0M | 593,043 | 0.2% |
| Vyne Therapeutics Inc(VYNE) | COM | 92941V308 | $2.6M | 1,394,336 | 0.1% |
| Verve Therapeutics Inc | COM | 92539P101 | $1.7M | 350,000 | 0.1% |
| Artiva Biotherapeutics Inc(ARTV) | COM | 04317A107 | $1.6M | 103,633 | 0.1% |
| Rapt Therapeutics Inc(RAPTEUR) | COM | 75382E109 | $998.5K | 496,750 | 0.1% |